Advanced data still arrives in silos
Genetics, imaging, conventional biomarkers and wearables often lack a shared timeline or analytical model.
Partner audience · Longevity clinics
Health span is a trajectory. The data should be longitudinal too.
Longevity clinics already connect genetics, imaging, biomarkers and intervention. miRoncol adds a microRNA control-layer perspective that can support a current oncology application now and a broader history of molecular change as research develops.
Longitudinal, cardiovascular, neurodegenerative and metabolic applications described by miRoncol remain research directions and should not be marketed as current clinical tests.
Clinic objectiveProtect more healthy years
Current applicationPhysician-guided oncology screening
Distinct advantageEstablished longitudinal relationships
Research expansionFour major chronic disease areas
Why longevity is more than a test menu
The greatest value comes from connecting measurements into an interpretable history.
Adding another biomarker is not enough. The program should clarify what each measure contributes and how evidence changes across time.
microRNA adds a different biological view
Regulatory patterns may offer information upstream of many familiar downstream markers.
The clinic relationship preserves context
Annual or structured follow-up creates the opportunity to distinguish personal stability, change and intervention.
How it fits into a longevity program
Start with a validated question. Preserve the broader profile for future learning.
NGS and PCR can serve different jobs, while the clinical program keeps every result within context.
Use current applications as intended
Keep miCheckup eligibility, performance and follow-up distinct from future platform research.
Establish healthy baseline
Capture the profile before a major health change so later comparisons have a personal reference.
Preserve broad information
NGS research profiles may be revisited as new signatures and disease questions emerge.
Translate focused assays
When a signature is validated, targeted PCR may support an accessible disease-specific application.
What this partnership creates
A high-context clinical channel for a platform designed to compound over time.
Longevity programs naturally align with early baseline capture, repeat engagement and a multi-disease view of health span.
A molecular history, not isolated reports
Results can be organized around personal baseline, clinical events and the broader health-span plan.
A differentiated longitudinal layer
The clinic can connect current testing with a scientifically bounded roadmap for future measurement and research.
A natural multi-disease setting
Oncology, cardiovascular, neurodegenerative and metabolic disease all matter to long-term health span and require independent validation.
Scientific discipline in longevity
The future-facing story must remain separate from current clinical claims.
Longevity audiences are receptive to innovation, which makes evidence boundaries and transparent language especially important.
Use now
Validated, bounded applications
- Follow current product intended use and eligibility.
- Use physician review for results.
- Continue standard screening and primary care.
- Separate clinical service from optional research consent.
Research horizon
Promising but not yet a product
- Longitudinal interpretation requires validation.
- Other disease branches remain research directions.
- Intervention-response examples are illustrative.
- Broad profiles do not automatically generate clinical findings.
Build the history early
Create a longevity program that preserves context as science advances.
Start with the current workflow and define where clinical service ends and consented research begins.